Ben Klieve

Brett Reiss

Scott Henry

- Evogene reported **revenues of approximately $3.2 million** for the six months ended June 30, 2025, an increase from **$2.3 million** in the prior year, while its overall loss decreased by **21.4%** to approximately **$7.7 million**.  **[1574565_0001178913-25-003427_exhibit_99-1.htm:1]** **[1574565_0001178913-25-003427_exhibit_99-2.htm:4]** **[1574565_0001178913-25-003427_exhibit_99-2.htm:6]** 
- The company is undergoing a strategic shift, focusing on its ChemPass AI tech-engine, which includes integrating AgPlenus's activities into Evogene and implementing **workforce reductions of 40% at AgPlenus and 30% at Evogene**, with the full effect expected in the second half of 2025.  **[1574565_0001178913-25-003427_exhibit_99-2.htm:2]** 
- On July 8, 2025, Evogene completed the sale of most of Lavie Bio's activities and the MicroBoost AI Tech-Engine for agriculture to an ICL affiliate for a total consideration of approximately **$18.714 million**.  **[1574565_0001178913-25-003427_exhibit_99-2.htm:3]** **[1574565_0001178913-25-003427_exhibit_99-1.htm:5]** **[1574565_0001178913-25-003427_exhibit_99-1.htm:7]** **[1574565_0001178913-25-003427_exhibit_99-1.htm:19]** **[1574565_0001178913-25-003427_exhibit_99-1.htm:20]** 
- As of June 30, 2025, Evogene held approximately **$11.9 million** in cash and cash equivalents and short-term bank deposits, which management believes will be sufficient to meet projected cash requirements for at least the next 12 months.  **[1574565_0001178913-25-003427_exhibit_99-2.htm:6]** **[1574565_0001178913-25-003427_exhibit_99-2.htm:7]** 
- A **1-for-10 reverse share split** was effected after market close on **July 24, 2024**, retroactively adjusting all share and per share amounts presented.  **[1574565_0001178913-25-003427_exhibit_99-2.htm:4]** **[1574565_0001178913-25-003427_exhibit_99-1.htm:7]**

Evogene (EVGN)